PR Newswire Clinical TrialsOriginal article
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Data ReadoutpositivePositive
AI Analysis
Summary
Kazia Therapeutics reported positive early clinical data showing a 100% clinical benefit rate in six patients with advanced triple-negative breast cancer, with durable metabolic responses and significant reductions in circulating tumor cell clusters and exhausted T cells without serious adverse events.
Clinical Trial Data
Primary Endpoint
Met
Patients
6
Outcome Details
100% clinical benefit rate in initial six patients with durable complete metabolic response, median 83% reduction in metastasis-associated CTC clusters and 51% reduction in terminally exhausted T cells, no treatment-related serious adverse events
Importance:6/10
Sentiment:
0.85
early-stage dataoncologytriple-negative breast cancerimmunotherapyCTC monitoringsmall patient cohort
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 27, 2026 8:01 PM